u/mikkel_ogunleye
Contributes reviews on supplier material. Based in Coimbra.
member · joined 16 Jul 2025
Comments — page 2 of 2
comment on [PSA] GIP is not what most of this community thinks it is in c/tirzepatide · 13 points · 1 year ago
the trials titrated on a calendar, real people titrate on symptoms
comment on the fake COA question that gets asked weekly, answered properly in c/scamalerts · 20 points · 1 year ago
Hunan GoodPeptides Biotech gets named here constantly and there is nothing verifiable on file either way
comment on help me understand ALT, I have read the wiki twice in c/bloodwork · 12 points · 1 year ago
Same lab as the previous draw?
comment on how much of what we believe about dual agonist actually comes from GIP threads in c/tirzepatide · 71 points · 1 year ago
Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.
comment on help me understand 15mg, I have read the wiki twice in c/tirzepatide · 125 points · 1 year ago
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme.
Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.
comment on help me understand 15mg, I have read the wiki twice in c/tirzepatide · 334 points · 1 year ago
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
comment on the ApoB thing finally clicked for me and I want to write it down in c/bloodwork · 131 points · 1 year ago
I would not draw a line through two points, especially when the second was taken at a different time of day.
comment on [Discussion] dual agonist is doing more work than we give it credit for in c/tirzepatide · 18 points · 1 year ago
the early fullness profile is genuinely gentler than people expect coming from sema
comment on reading ALT threads from 2024 and half of it aged badly in c/bloodwork · 18 points · 1 year ago
This. Reference ranges are population intervals, not targets, and conflating them causes a lot of unnecessary alarm here.
comment on [Discussion] the fraud advice in here is 2 years out of date in c/scamalerts · 12 points · 1 year ago
Now I buy small from anyone new, test it, and only then commit. It has cost me a few small orders and saved me one large one.
comment on [Meta] the tirzepatide rule is doing its job and people should stop complaining in c/tirzepatide · 56 points · 2 years ago
if 7.5 is working, 10 is not automatically better
comment on am I the only one who found tirzepatide harder than the injections in c/tirzepatide · 50 points · 2 years ago
Correction to my own post above — I said 5mg and I have been on 2.5mg since the spring. Same argument, wrong number.
comment on [Discussion] can we stop arguing about fraud until somebody posts a number in c/scamalerts · 479 points · 2 years ago
Careful. What you are describing is a delayed shipment, and this board should not turn that into an accusation without more.
comment on [Lab] split one vial across Medutest and Janoshik — 98.3% and 98.7% in c/tirzepatide · 34 points · 2 years ago
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
comment on [Lab] split one vial across Medutest and Janoshik — 98.3% and 98.7% in c/tirzepatide · 44 points · 2 years ago
Did you come to this from sema, and if so how long was the gap?
comment on [Lab] split one vial across Medutest and Janoshik — 98.3% and 98.7% in c/tirzepatide · 201 points · 2 years ago
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
comment on [Discussion] we are measuring GIP at the wrong time and calling it noise in c/tirzepatide · 1 points · 2 years ago
Pen or vial? The step sizes available differ and it changes this answer.